Iovance Biotherapeutics Inc (IOVA)

$2.27 0.00 (N/A)
Market Cap 821.41M
Revenue (ttm) 164.07M
Net Income (ttm) -372.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -226.84%
Debt to Equity Ratio 0.00
Volume 6,333,400
Avg Vol 18,218,971
Day's Range N/A - N/A
Shares Out 361.85M
Stochastic %K 41%
Beta 0.82
Analysts Sell
Price Target $9.10

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanom...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
lovemeLUNGtime
lovemeLUNGtime Sep. 16 at 10:48 AM
$IOVA TILVANCE-301 (lifileucel + Keytruda vs Keytruda in 1L melanoma) readout in 2H 2025 is the key catalyst — it could convert Amtagvi’s approval to full and unlock 1L market share. Second major 2H 2025 event: IOV-LUN-202 Phase 2 data in NSCLC, aimed at an accelerated approval path and opening a multi-billion-dollar lung cancer market.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 16 at 10:37 AM
Enter: $IOVA OCT 10 2025 $2 CALLS Buy in Price: $0.25 - $0.26 Take Profit: $0.28 Stop Bleeding: $0.22 ROI Potential: 10% Exit Within: 66 Minutes https://moneygroup.us/alerts
0 · Reply
ManlikeProf
ManlikeProf Sep. 16 at 10:31 AM
$IOVA Royal Marsden hospital in the UK, Remember I said this few days ago?? lol..... IOVA is seriously undervalued. https://www.royalmarsden.nhs.uk/news-and-events/news/one-time-cell-therapy-offers-long-term-survival-hope-patients-advanced
0 · Reply
Dorps332
Dorps332 Sep. 16 at 10:23 AM
$IOVA as of now we are scheduled for the 7th annual TIL summit on November 10-13. They have not announce it yet but we are on the website. https://til-therapies.com/?utm_source=digital&utm_medium=ppc&utm_campaign=other-home&utm_content=google%2Fev-59783&gad_source=1&gad_campaignid=22900827079&gbraid=0AAAAABOWfabBcFmFSmF4gG24gqtAtGbx4&gclid=CjwKCAjwlaTGBhANEiwAoRgXBXgM7a9DVROcSbBVJ3y7mZSPIX7Q9eCrrmLe7s0zJFsK3ibxbAohtxoC3OAQAvD_BwE
1 · Reply
Dorps332
Dorps332 Sep. 16 at 10:15 AM
$IOVA old article but a good one. https://www.uchealth.org/today/she-was-dying-of-melanoma-until-a-new-treatment-called-til-therapy/
0 · Reply
Kramer900
Kramer900 Sep. 16 at 9:36 AM
$IOVA
1 · Reply
zongo
zongo Sep. 16 at 8:46 AM
$IOVA https://inspirogene.com/wp-content/uploads/2025/09/InspiroGene-by-McKesson-Selected-as-the-Specialty-Pharmacy-Partner-for-Iovances-Amtagvi-First-Cell-Therapy-Approved-for-Solid-Tumors.pdf?_gl=1%2Axi3pl6%2A_up%2AMQ..%2A_gs%2AMQ..&gbraid=0AAAAA9kVbUBQyzwl1kETc3yVmh2j4vVSv
0 · Reply
Lastcall
Lastcall Sep. 16 at 8:40 AM
$IOVA This been seen already ? Iovance Biotherapeutics Partners with InspiroGene for Expanded Access to Amtagvi Cell Therapy Reuters 09/15/2025 10:22 Follow IOVA 0.00% InspiroGene by McKesson has been selected as the specialty pharmacy partner for Iovance Biotherapeutics Inc.'s Amtagvi®, marking the first cell therapy approved for solid tumors. This partnership aims to increase access for patients with advanced melanoma. By leveraging Biologics by McKesson's extensive experience in specialty pharmacy and oncology, the collaboration seeks to reduce administrative burdens for providers and expand patient access to this innovative therapy. Amtagvi is the only FDA-approved one-time tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, providing a personalized treatment option for patients who have undergone immune checkpoint inhibitor and targeted therapy. Through this partnership, Iovance aims to efficiently deliver life-extending therapies to more patients.
1 · Reply
MetaverseMaven
MetaverseMaven Sep. 16 at 7:08 AM
$IOVA Outlook hinges on demand recovery and product adoption over the next 12-18 months
0 · Reply
Rollercoaster22
Rollercoaster22 Sep. 16 at 7:07 AM
$IOVA The stockprice and the manipulation is beyond depressing. Guess the majority of us are more or less bagholders, but when I think of their science and how unique it is and that they don't have any competion yet, well, then it's impossible not being bullish. The cherry on the pie is their pipeline AND that the mangament have understood that it doesn't matter if they have the best treatment in the world if they missmanage the company. They will lose it all and people who could have survived will die. I try hard not to let the shorts get to me and it's easier said then done, but I know that few biotechs out there have IOVA's potential, so I will wait, because patience will my/our reward. And that's a fact and no speculation. We have seen over and over again.
1 · Reply
Latest News on IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences

Aug 29, 2025, 8:30 AM EDT - 17 days ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Aug 22, 2025, 5:15 PM EDT - 24 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Aug 21, 2025, 4:56 PM EDT - 25 days ago

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 18, 2025, 4:15 PM EDT - 4 weeks ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:15 AM EDT - 5 weeks ago

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Aug 7, 2025, 4:01 PM EDT - 5 weeks ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 23, 2025, 12:08 PM EDT - 7 weeks ago

Here's why Iova stock surged 32% today and why the rally might not be over

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Jul 18, 2025, 12:02 PM EDT - 2 months ago

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 15, 2025, 7:30 AM EDT - 2 months ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 9:04 AM EDT - 2 months ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 14, 2025, 7:30 AM EDT - 2 months ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 11, 2025, 10:32 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 2 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 10, 2025, 8:18 AM EDT - 2 months ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 3, 2025, 7:35 AM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

Jul 2, 2025, 5:46 PM EDT - 2 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 28, 2025, 7:46 AM EDT - 2 months ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Jun 26, 2025, 4:45 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

Jun 26, 2025, 9:00 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jun 24, 2025, 12:03 PM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 20, 2025, 9:07 AM EDT - 3 months ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

Jun 18, 2025, 2:34 PM EDT - 3 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 18, 2025, 8:38 AM EDT - 3 months ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 3 months ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

Jun 10, 2025, 8:47 AM EDT - 3 months ago

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

Iovance Biotherapeutics to Present at Upcoming Conference

Jun 10, 2025, 8:45 AM EDT - 3 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA)

Jun 8, 2025, 8:18 AM EDT - 3 months ago

IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA)

lovemeLUNGtime
lovemeLUNGtime Sep. 16 at 10:48 AM
$IOVA TILVANCE-301 (lifileucel + Keytruda vs Keytruda in 1L melanoma) readout in 2H 2025 is the key catalyst — it could convert Amtagvi’s approval to full and unlock 1L market share. Second major 2H 2025 event: IOV-LUN-202 Phase 2 data in NSCLC, aimed at an accelerated approval path and opening a multi-billion-dollar lung cancer market.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 16 at 10:37 AM
Enter: $IOVA OCT 10 2025 $2 CALLS Buy in Price: $0.25 - $0.26 Take Profit: $0.28 Stop Bleeding: $0.22 ROI Potential: 10% Exit Within: 66 Minutes https://moneygroup.us/alerts
0 · Reply
ManlikeProf
ManlikeProf Sep. 16 at 10:31 AM
$IOVA Royal Marsden hospital in the UK, Remember I said this few days ago?? lol..... IOVA is seriously undervalued. https://www.royalmarsden.nhs.uk/news-and-events/news/one-time-cell-therapy-offers-long-term-survival-hope-patients-advanced
0 · Reply
Dorps332
Dorps332 Sep. 16 at 10:23 AM
$IOVA as of now we are scheduled for the 7th annual TIL summit on November 10-13. They have not announce it yet but we are on the website. https://til-therapies.com/?utm_source=digital&utm_medium=ppc&utm_campaign=other-home&utm_content=google%2Fev-59783&gad_source=1&gad_campaignid=22900827079&gbraid=0AAAAABOWfabBcFmFSmF4gG24gqtAtGbx4&gclid=CjwKCAjwlaTGBhANEiwAoRgXBXgM7a9DVROcSbBVJ3y7mZSPIX7Q9eCrrmLe7s0zJFsK3ibxbAohtxoC3OAQAvD_BwE
1 · Reply
Dorps332
Dorps332 Sep. 16 at 10:15 AM
$IOVA old article but a good one. https://www.uchealth.org/today/she-was-dying-of-melanoma-until-a-new-treatment-called-til-therapy/
0 · Reply
Kramer900
Kramer900 Sep. 16 at 9:36 AM
$IOVA
1 · Reply
zongo
zongo Sep. 16 at 8:46 AM
$IOVA https://inspirogene.com/wp-content/uploads/2025/09/InspiroGene-by-McKesson-Selected-as-the-Specialty-Pharmacy-Partner-for-Iovances-Amtagvi-First-Cell-Therapy-Approved-for-Solid-Tumors.pdf?_gl=1%2Axi3pl6%2A_up%2AMQ..%2A_gs%2AMQ..&gbraid=0AAAAA9kVbUBQyzwl1kETc3yVmh2j4vVSv
0 · Reply
Lastcall
Lastcall Sep. 16 at 8:40 AM
$IOVA This been seen already ? Iovance Biotherapeutics Partners with InspiroGene for Expanded Access to Amtagvi Cell Therapy Reuters 09/15/2025 10:22 Follow IOVA 0.00% InspiroGene by McKesson has been selected as the specialty pharmacy partner for Iovance Biotherapeutics Inc.'s Amtagvi®, marking the first cell therapy approved for solid tumors. This partnership aims to increase access for patients with advanced melanoma. By leveraging Biologics by McKesson's extensive experience in specialty pharmacy and oncology, the collaboration seeks to reduce administrative burdens for providers and expand patient access to this innovative therapy. Amtagvi is the only FDA-approved one-time tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, providing a personalized treatment option for patients who have undergone immune checkpoint inhibitor and targeted therapy. Through this partnership, Iovance aims to efficiently deliver life-extending therapies to more patients.
1 · Reply
MetaverseMaven
MetaverseMaven Sep. 16 at 7:08 AM
$IOVA Outlook hinges on demand recovery and product adoption over the next 12-18 months
0 · Reply
Rollercoaster22
Rollercoaster22 Sep. 16 at 7:07 AM
$IOVA The stockprice and the manipulation is beyond depressing. Guess the majority of us are more or less bagholders, but when I think of their science and how unique it is and that they don't have any competion yet, well, then it's impossible not being bullish. The cherry on the pie is their pipeline AND that the mangament have understood that it doesn't matter if they have the best treatment in the world if they missmanage the company. They will lose it all and people who could have survived will die. I try hard not to let the shorts get to me and it's easier said then done, but I know that few biotechs out there have IOVA's potential, so I will wait, because patience will my/our reward. And that's a fact and no speculation. We have seen over and over again.
1 · Reply
Rollercoaster22
Rollercoaster22 Sep. 16 at 6:50 AM
$IOVA
0 · Reply
Rollercoaster22
Rollercoaster22 Sep. 16 at 6:33 AM
$IOVA
0 · Reply
KangaroooJack
KangaroooJack Sep. 16 at 4:00 AM
$IOVA
0 · Reply
HamBoneXoXo
HamBoneXoXo Sep. 16 at 3:28 AM
$IOVA This ticker/company is stuck in multiple muds with no easy or quick way out. So enjoy the $831 mil market cap as it really should be half as large. And stop fantasizing about a white horse. No big pharma is dumb enough to jump into this sinking ship.
1 · Reply
Kramer900
Kramer900 Sep. 16 at 3:00 AM
$IOVA anyone that doesn't see the manipulation here is blind. Just like people that think we live on a sphere.
0 · Reply
tedevan
tedevan Sep. 16 at 2:37 AM
$IOVA
0 · Reply
Pacificview
Pacificview Sep. 16 at 2:35 AM
$IOVA For our nervous nilleys out there. Dr. Rachesky is our 2nd largest shareholder through MHR. He owns 28,000,000 shares at an average cost of about $6 ish. HIS LAST PURCHASE OF 4,500,000 shares was on June 30th 2025. He has been buying hand over fist since December 2022. Eleven different purchase's from $1.72 all the way to $14.82 He likes what he see's, so my long friends we are in good company. The good Doctor knows a great deal when he see's one.
3 · Reply
HeadSpin101
HeadSpin101 Sep. 16 at 1:49 AM
$IOVA Wayne needs to buy a big chunk. He owes it to the shareholders as Freddy F*cK is his frontman. If he had let IOVA hire a real CEO we wouldn’t be at these levels. Wayne show some conviction like Duggar!
2 · Reply
KangaroooJack
KangaroooJack Sep. 16 at 1:47 AM
$IOVA preface I’m not going anywhere. But anyone with a close eye on institutions, wondering your thoughts on the avg. -50% position haircuts I’m seeing across almost all tutes. I don’t understand that down here at these prices, all because an ER miss? Was hoping to see tutes double, triple down, but instead ~50% haircuts down here at these lows.. it pisses me off. Scroll down and see for yourself if you haven’t seen Reference: https://fintel.io/so/us/iova
1 · Reply
locallab
locallab Sep. 15 at 11:59 PM
$IOVA
0 · Reply
biostockhunter
biostockhunter Sep. 15 at 11:57 PM
$IOVA per Dan Kirby, August ER. Substantial queue of patients for newly opened quality ATC. Not sure what to make of it, will it be a cherry on top upside this November quarter. Coupled with the McKesson news. If so I don't feel like infusion count will be lower..
1 · Reply
egolden08
egolden08 Sep. 15 at 11:48 PM
$IOVA started nibbling on Thursday & Friday. I like the relatively small trading volumes at these levels. Tutes may finally be satiated… we’ll see. If not, I’ll buy more.
1 · Reply